Synairgen has raised £14.0m to fund a Phase II trial for SNG001 in COVID-19 disease, which is due to commence enrolment imminently after gaining rapid permissions for the UK’s MHRA and HRA. This is a significant breakthrough for the company and the global fight against COVID-19, having achieved these permissions ahead of the expected rapid increase in number of hospitalised COVID-19 patients. A successful outcome from the pilot phase will have substantial commercial value. The ris
26 Mar 2020
Synairgen - £14m placing to fund COVID-19 activities
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Synairgen - £14m placing to fund COVID-19 activities
Synairgen plc (SNG:LON) | 5.2 0 0.0% | Mkt Cap: 10.6m
- Published:
26 Mar 2020 -
Author:
Mark Brewer | Cavendish Research -
Pages:
16
Synairgen has raised £14.0m to fund a Phase II trial for SNG001 in COVID-19 disease, which is due to commence enrolment imminently after gaining rapid permissions for the UK’s MHRA and HRA. This is a significant breakthrough for the company and the global fight against COVID-19, having achieved these permissions ahead of the expected rapid increase in number of hospitalised COVID-19 patients. A successful outcome from the pilot phase will have substantial commercial value. The ris